A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-30 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Expense must also be duly considered with such assays as they become more frequently applied in very large studies (e.g. potentially involving thousands of samples). While other approaches are also being made commercially available (e.g. iterative mapping of peptides, fluorescent variation of Edman degradation, and nanopores) these (i) remain broadly untested outside the firms involved; (ii) yield largely, if not completely, only proteogenomic data; (iii) are thus, currently at least, quite limited in terms of any capacity for a broad assessment of proteoforms; (iv) are dependent on the quality of the affinity or other (multiple) reagents required which; (v) tends to also increase costs per assay to the consumer. Notably, while promising, nanopore sequencing is (i) still quite early in development; and (ii) remains unproven in terms of throughput and capacity to address the full range of known PTM and adducts. Thus, the capacity for nanopores to quantitatively address the full breadth of a proteome remains untested. Other technical issues such as potential clogging of pores will also need to be addressed with hopefully routine solutions.
== Function == Κ-casein is involved in several important physiological processes in milk. Chymosin (found in rennet) cleaves κ-casein into an insoluble peptide, para-κ-casein, and a water-soluble glycomacropeptide (GMP). Milk-clotting proteases act on the soluble portion of κ-casein, generating an unstable micellar state that results in clot formation.
Analytes that are totally excluded, elute with the free volume outside around the particles (Vo), the total exclusion limit, while analytes that are completely delayed, elute with the solvent, marking the total permeation volume of the column, including also the solvent held inside the pores (Vi). The total volume can be considered by the following equation, where Vg is the volume of the polymer gel and Vt is the total volume:
Sources: en.wikipedia.org
=== Other === Photon correlation spectroscopy/Dynamic light scattering (DLS) Terahertz spectroscopy (THz) Electron paramagnetic/spin resonance (EPR, ESR) Small-angle neutron scattering (SANS) Rutherford backscattering spectrometry (RBS) Spatially resolved acoustic spectroscopy (SRAS)
== Adverse effects == Most side effects are direct consequences of the vasodilation and the resultant low blood pressure. They include headache ("nitrate headache") resulting from the widening of blood vessels in the brain, reflex tachycardia (fast heart rate), flush, dizziness, nausea and vomiting. These effects usually subside after a few days if the treatment is continued. Occasionally, severe hypotension occurs shortly after beginning of treatment, possibly resulting in intensified angina symptoms or syncope, sometimes with bradycardia (slow heart rate).
The adrenal glands are located above the kidneys in humans and in front of the kidneys in other animals. The adrenal glands produce a variety of hormones including adrenaline and the steroids aldosterone cortisol and Dehydroepiandrosterone sulfate (DHEA). Adrenaline increases blood pressure, heart rate, and metabolism in reaction to stress, the aldosterone controls the body's salt and water balance, the cortisol plays a role in stress response and the dehydroepiandrosterone sulfate (DHEA) produces aids in production of body odor and growth of body hair during puberty.
Myomeres are overlapping "cones" of muscle fibers bound by connective tissue. The shape of myomeres varies by species. Myomeres are commonly zig-zaged, being stacks or lines of muscle fibers shaped like "V" (lancelets), "W" (fishes), or straight (tetrapods). Generally, cyclostome myomeres are arranged in vertical strips while those of jawed fishes are folded in a complex manner due to their derived nature and evolution of advanced swimming capability. Specifically, myomeres of elasmobranchs and eels are W-shaped, while the myomeres of tetrapods, such as mudpuppies, run vertically and do not display complex folding. Myomeres overlap each other in succession, meaning myomere activation also allows neighboring myomeres to activate. They are innervated by spinal nerves, which pass into each myomere. Myomeres are made up of myoglobin-rich dark muscle as well as white muscle. Dark muscles generally function as slow-twitch muscle fibers while white muscle is composed of fast-twitch fibers. In gnathostomes, the myomeres are separated by myoseptal tendons. Specifically, these are the myorhabdoid tendons, the lateral tendons, the epineural tendon, and the epipleural tendon.
Sources: en.wikipedia.org
In Japan, both houses of today's national parliament, the National Diet (Kokkai), are directly elected, and although the two chambers differ in legislative and political authority, term length and age restriction of eligibility, the members of both houses are generally equal in personal status (financial compensation, immunity, etc.). There are currently 713 members of the National Diet (Kokkai giin, 国会議員): 465 members of the House of Representatives (Shūgiin giin, 衆議院議員) and 248 members of the House of Councillors (Sangiin giin, 参議院議員). The former are elected in general/by-/repeat elections of members of the House of Representatives (Shūgiin giin sō-/hoketsu-/sai-senkyo), the latter in regular/by-/repeat elections of members of the House of Councillors (Sangiin giin tsūjō-/hoketsu-/sai-senkyo). Under the 1947 constitution, the prime minister is elected by the National Diet and must be a member of the National Diet, as must the majority of other ministers; by practice, all prime ministers since 1947 have been members of the House of Representatives so far.
The B cells migrate to the nodular cortex and medulla. The T cells migrate to the deep cortex. This is a region of a lymph node called the paracortex that immediately surrounds the medulla. Because both naive T cells and dendritic cells express CCR7, they are drawn into the paracortex by the same chemotactic factors, increasing the chance of T cell activation. Both B and T lymphocytes enter lymph nodes from circulating blood through specialized high endothelial venules found in the paracortex.
=== International growth: 2010s === The market for electronic cigarettes rose rapidly during the early 2010s and it started gaining attention in mainstream media. International tobacco companies dismissed e-cigarettes as a fad at first, but, recognizing a potential new market sector that could make smoking obsolete, they began to produce and market their own brands of e-cigarettes and acquire existing e-cigarette companies. Tobacco companies bought established e-cigarette companies. Blu eCigs, a prominent US e-cigarette manufacturer, was acquired by Lorillard Inc. for $135 million in April 2012. Japan Tobacco invested in Ploom. British American Tobacco was the first tobacco business to sell e-cigarettes in the UK and launched the e-cigarette Vype in July 2013. Imperial Tobacco's Fontem Ventures acquired the intellectual property owned by Hon Lik through Dragonite International Limited for $US 75 million in 2013 and launched Puritane in partnership with Boots UK. On 1 October 2013 Lorillard Inc. acquired another e-cigarette company, this time the UK based company SKYCIG. SKY was rebranded as blu.
In computer science, in situ refers to the use of technology and user interfaces to provide continuous access to situationally relevant information across different locations and contexts. Examples include athletes viewing biometric data on smartwatches to improve their performance or a presenter looking at tips on a smart glass to reduce their speaking rate during a speech. An algorithm is said to be an in situ algorithm, or in-place algorithm, if the extra amount of memory required to execute the algorithm is O(1). With big data, in situ data would mean bringing the computation to where data is located, rather than the other way like in traditional RDBMS systems where data is moved to computational space.
Existential risk researchers analyze risks that could lead to human extinction or civilizational collapse, and look for ways to build resilience against them. Relevant research centers include the Cambridge Center for the Study of Existential Risk and the Stanford Existential Risk Initiative. Future technologies may contribute to the risks of artificial general intelligence, biological warfare, nuclear warfare, nanotechnology, anthropogenic climate change, global warming, or stable global totalitarianism, though technologies may also help to mitigate asteroid impacts and gamma-ray bursts. In 2019, philosopher Nick Bostrom introduced the notion of a vulnerable world, "one in which there is some level of technological development at which civilization almost certainly gets devastated by default", citing the risks of a pandemic caused by bioterrorists, or an arms race triggered by the development of novel armaments and the loss of mutual assured destruction. He invites policymakers to question the assumptions that technological progress is always beneficial, that scientific openness is always preferable, or that they can afford to wait until a dangerous technology has been invented before they prepare mitigations.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.